Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Persistent infection with high risk genotypes of human papillomavirus (HPV) is the cause of cervical cancer, one of most common cancer among woman worldwide, and represents an important risk factor associated with other anogenital and oropharyngeal cancers in men and women. Here, we designed a therapeutic vaccine based on integrase defective lentiviral vector (IDLV) to deliver a mutated nononcogenic form of HPV16 E7 protein, considered as a tumor specific antigen for immunotherapy of HPV‐associated cervical cancer, fused to calreticulin (CRT), a protein able to enhance major histocompatibility complex class I antigen presentation (IDLV‐CRT/E7). Vaccination with IDLV‐CRT/E7 induced a potent and persistent E7‐specific T cell response up to 1 year after a single immunization. Importantly, a single immunization with IDLV‐CRT/E7 was able to prevent growth of E7‐expressing TC‐1 tumor cells and to eradicate established tumors in mice. The strong therapeutic effect induced by the IDLV‐based vaccine in this preclinical model suggests that this strategy may be further exploited as a safe and attractive anticancer immunotherapeutic vaccine in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector
Negri, D. R., Michelini, Z., Baroncelli, S., Spada, M., Vendetti, S., Buffa, V., Bona, R., Leone, P., Klotman, M. E., & Cara, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300241 · Cited by 84
Self-citationProtective Antiviral Immunity Conferred by a Nonintegrative Lentiviral Vector-Based Vaccine
Coutant, F., Frenkiel, M.-P., Despres, P., & Charneau, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003973 · Cited by 70
Cited by
Xu, Z., Wang, Y., Zhang, L., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn500216y · Cited by 284
Design and potential of non-integrating lentiviral vectors
Shaw, A., & Cornetta, K. (2014) · Biomedicines · doi:10.3390/biomedicines2010014 · Cited by 60
“Cells [118]”
BackgroundThe old and the new: Prospects for non-integrating lentiviral vector technology
Apolonia, L. (2020) · Viruses · doi:10.3390/v12101103 · Cited by 58
“Several pre-clinical studies have shown the efficacy of NILVs in raising an immune response against HIV-1 [77,79–82], influenza virus [83–85], Zika virus [86], human papillomavirus [87], vaccinia virus [88], West Nile virus [89], human cytomegalovirus [90], Hepatitis B virus [75], and malaria [91].”
Coutant, F., Sanchez David, R. Y., Félix, T., Boulay, A., Caleechurn, L., Souque, P., Thouvenot, C., Bourgouin, C., Beignon, A.-S., & Charneau, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048644 · Cited by 32
“It was also reported that mice immunized with NILV mount potent CD8+ T cells against various antigens, such as HIV-1 gp120 and gag, HBsAg or OVA and hgp100, which mediate effective tumor prophylaxis and therapy [48,49,50,51,52,53].”
BackgroundGallinaro, A., Borghi, M., Pirillo, M. F., Cecchetti, S., Bona, R., Canitano, A., Michelini, Z., Di Virgilio, A., Olvera, A., Brander, C., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.013 · Cited by 15
Self-citation
Metadata
- Authors
- Grasso, F., Negri, D. R. M., Mochi, S., Rossi, A., Cesolini, A., Giovannelli, A., Chiantore, M. V., Leone, P., Giorgi, C., & Cara, A.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2012-06-28
- Volume
- 132
- Issue
- 2
- Pages
- 335-344
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2071926438
- Cited by
- 48
- References
- 2
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.